AU2002226061B2 - Peptides for activation and inhibition of delta PKC - Google Patents

Peptides for activation and inhibition of delta PKC Download PDF

Info

Publication number
AU2002226061B2
AU2002226061B2 AU2002226061A AU2002226061A AU2002226061B2 AU 2002226061 B2 AU2002226061 B2 AU 2002226061B2 AU 2002226061 A AU2002226061 A AU 2002226061A AU 2002226061 A AU2002226061 A AU 2002226061A AU 2002226061 B2 AU2002226061 B2 AU 2002226061B2
Authority
AU
Australia
Prior art keywords
seq
peptide
ischemia
ischemic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002226061A
Other languages
English (en)
Other versions
AU2002226061A1 (en
Inventor
Leon Chen
Daria Mochly-Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2002226061A1 publication Critical patent/AU2002226061A1/en
Application granted granted Critical
Publication of AU2002226061B2 publication Critical patent/AU2002226061B2/en
Priority to AU2007231787A priority Critical patent/AU2007231787A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002226061A 2001-01-18 2001-11-09 Peptides for activation and inhibition of delta PKC Ceased AU2002226061B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007231787A AU2007231787A1 (en) 2001-01-18 2007-11-02 Peptides for activation and inhibition of delta PKC

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26206001P 2001-01-18 2001-01-18
US60/262,060 2001-01-18
PCT/US2001/047556 WO2002057413A2 (en) 2001-01-18 2001-11-09 Peptides for activation and inhibition of delta pkc

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007231787A Division AU2007231787A1 (en) 2001-01-18 2007-11-02 Peptides for activation and inhibition of delta PKC

Publications (2)

Publication Number Publication Date
AU2002226061A1 AU2002226061A1 (en) 2003-02-13
AU2002226061B2 true AU2002226061B2 (en) 2007-08-02

Family

ID=22995990

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226061A Ceased AU2002226061B2 (en) 2001-01-18 2001-11-09 Peptides for activation and inhibition of delta PKC

Country Status (6)

Country Link
US (5) US6855693B2 (enExample)
EP (2) EP2338899A1 (enExample)
JP (2) JP4115838B2 (enExample)
AU (1) AU2002226061B2 (enExample)
CA (1) CA2434643C (enExample)
WO (1) WO2002057413A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168354A1 (en) * 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
AU2002226061B2 (en) * 2001-01-18 2007-08-02 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta PKC
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
US7507711B2 (en) * 2002-04-22 2009-03-24 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
US20110002978A1 (en) * 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
US7700553B2 (en) * 2003-09-24 2010-04-20 Institut Pasteur Selective inhibition of NF-κB activation by peptides designed to disrupt nemo oligomerization
WO2005057213A1 (en) * 2003-12-09 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating mitochondrial aldehyde dehydrogenase-2
WO2005065666A1 (en) * 2003-12-22 2005-07-21 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Us of a pkc-delta inhibitor for the inhibition of metastatic melanoma
US20050267030A1 (en) * 2004-04-30 2005-12-01 Tsao Philip S Use of deltaPKC peptides for modulation of reactive oxygen species
JP2008508363A (ja) * 2004-08-02 2008-03-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー δプロテインキナーゼＣの調節のためのペプチド配列
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
AU2005325128A1 (en) 2005-01-04 2006-07-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
US20060160062A1 (en) * 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20090186814A1 (en) * 2005-01-26 2009-07-23 Fumiaki Ikeno Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
US9523688B2 (en) * 2005-03-07 2016-12-20 Laurence Faure Diagnosis method and treatment for cancer using liv21 proteins and E2F1/E2F4 biomarkers
WO2007027974A1 (en) * 2005-09-02 2007-03-08 The Board Of Trustees Of The Leland Stanford Junior University Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
EP2194124A1 (en) * 2005-09-19 2010-06-09 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
US20070148628A1 (en) * 2005-12-09 2007-06-28 Philadelphia College Of Osteopathic Medicine Organ preservation and/or perfusion
DK2056851T3 (da) * 2005-12-09 2013-10-14 Philadelphia College Of Osteopathic Medicine Organkonservering og/eller -perfusion
EP2069388A2 (en) 2006-10-02 2009-06-17 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the c2 domain of epsilon pkc, and use thereof
KR101552843B1 (ko) * 2006-11-16 2015-09-14 카이 파마슈티컬즈 부갑상선 기능항진증 및 고칼슘혈증 장애의 치료를 위한 폴리양이온성 칼슘 조절제 펩타이드
WO2008080153A2 (en) * 2006-12-22 2008-07-03 The Children's Hospital Of Philadelphia A novel protein kinase c therapy for the treatment of acute lung injury
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
ES2476842T3 (es) 2007-01-10 2014-07-15 Purdue Research Foundation Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos
CN103524623A (zh) * 2007-01-19 2014-01-22 凯制药公司 肽组合物的修饰以提高稳定性和递送效率
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
KR100906153B1 (ko) 2007-07-04 2009-07-03 재단법인 한국원자력의학원 프로테인 카이네즈 씨 활성 저해용 단백질 및 이를포함하는 약제학적 조성물
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
CA2698013A1 (en) * 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
CA2705862C (en) * 2007-11-16 2018-03-27 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
WO2010019965A1 (en) * 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
PT2459208T (pt) 2009-07-29 2017-01-03 Kai Pharmaceuticals Inc Agentes terapêuticos para redução dos niveis de hormona paratiroideia
WO2011041385A2 (en) 2009-09-29 2011-04-07 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
SMT201700081T1 (it) 2011-06-08 2017-03-08 Kai Pharmaceuticals Inc Agenti terapeutici per la regolazione del fosforo sierico
US9217137B2 (en) 2011-08-12 2015-12-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for specific regulation of pyruvate dehydrogenase kinase
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
KR101611494B1 (ko) 2012-12-20 2016-04-12 한양대학교 산학협력단 ＰＫＣ－δ 검출용 폴리펩티드 및 이의 용도
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
US20170044212A1 (en) * 2015-08-14 2017-02-16 Jingyi Wang Compound for treating sequelae of ischemic cerebral stroke
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
TW202146071A (zh) * 2020-03-31 2021-12-16 日商東麗股份有限公司 影像解析裝置、影像解析裝置的控制方法、影像解析系統、及影像解析系統的控制方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014038A1 (en) * 1995-10-10 1997-04-17 Terrapin Technologies, Inc. Methods to identify modulators of cell signaling
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) * 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5783405A (en) 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
AU2002226061B2 (en) * 2001-01-18 2007-08-02 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta PKC
US7224668B1 (en) * 2002-11-27 2007-05-29 Cisco Technology, Inc. Control plane security and traffic flow management
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
AU2005325128A1 (en) * 2005-01-04 2006-07-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
US20090186814A1 (en) * 2005-01-26 2009-07-23 Fumiaki Ikeno Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
CA2698013A1 (en) 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
WO1997014038A1 (en) * 1995-10-10 1997-04-17 Terrapin Technologies, Inc. Methods to identify modulators of cell signaling

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Csukai, M and Mochly-Rosen, D. Pharmacological Research, 1999, vol 39, pages 253-259 *
Inagaki, K. et al., Circulation, 2000, vol 101, pages 797-804 *
Johnson, J. A. et al., Journal of Biological Chemistry, 1996, vol 271, pages 24962- 24966 *
Way, K. K. et al., Trends in Pharmacological Sciences, 2000, vol 21, pages 181-187 *

Also Published As

Publication number Publication date
US6855693B2 (en) 2005-02-15
WO2002057413A2 (en) 2002-07-25
JP2004521108A (ja) 2004-07-15
EP1351980B1 (en) 2014-12-31
JP2008231103A (ja) 2008-10-02
US7851586B2 (en) 2010-12-14
JP4115838B2 (ja) 2008-07-09
US20090192089A1 (en) 2009-07-30
US7915219B2 (en) 2011-03-29
CA2434643C (en) 2013-10-29
EP1351980A4 (en) 2005-02-02
US20020150984A1 (en) 2002-10-17
JP4592772B2 (ja) 2010-12-08
US7745388B2 (en) 2010-06-29
EP1351980A2 (en) 2003-10-15
US20040204364A1 (en) 2004-10-14
US20110143991A1 (en) 2011-06-16
WO2002057413A3 (en) 2003-04-03
US8822636B2 (en) 2014-09-02
US20090075901A1 (en) 2009-03-19
EP2338899A1 (en) 2011-06-29
CA2434643A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AU2002226061B2 (en) Peptides for activation and inhibition of delta PKC
AU2002226061A1 (en) Peptides for activation and inhibition of delta PKC
US7985726B2 (en) ψεRACK peptide composition and method for protection against tissue damage due to ischemia
AU2003234185B2 (en) Peptide inhibitors of protein kinase C
AU2001297950B2 (en) psi-epsilon RACK peptide composition and method for protection against tissue damage due to ischemia
AU2007231787A1 (en) Peptides for activation and inhibition of delta PKC
AU2001297950A1 (en) psi-epsilon RACK peptide composition and method for protection against tissue damage due to ischemia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired